Myeloma Bone Disease
This state-of-the-art book presents the forefront in the science and clinical management of myeloma bone disease. Assembling the work of the world's premier thought leaders, this book begins with sections on clinical presentation, imaging, and
- PDF / 6,978,634 Bytes
- 257 Pages / 499.673 x 773.353 pts Page_size
- 17 Downloads / 177 Views
G. David Roodman
Myeloma Bone Disease Myeloma Cells
(+)
(–)
(+) Stromal Cells
Osteoclasts
Osteoblasts
Myeloma Bone Disease
CURRENT CLINICAL ONCOLOGY Maurie Markman, MD, S ERIES E DITOR
For other titles published in this series, go to www.springer.com/series/7631
Myeloma Bone Disease Edited by
G. David Roodman University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Editor G. David Roodman Department of Medicine University of Pittsburgh Medical Center Pittsburgh, PA USA [email protected]
ISBN 978-1-60761-553-8 e-ISBN 978-1-60761-554-5 DOI 10.1007/978-1-60761-554-5 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010921111 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface
Multiple myeloma is the second most common hematologic malignancy and currently affects approximately 50,000 people in the United States. Each year about 20,000 people are diagnosed with myeloma. Although new treatments have been developed, which significantly prolong the survival of patients, myeloma bone disease still remains a major cause of severe morbidity and increased mortality in patients with myeloma. Myeloma bone disease is characterized by “punched out” lytic lesions caused by increased osteoclastic bone destruction accompanied by suppressed or even absent osteoblast activity. Advances in our understanding of both the pathophysiology of myeloma bone disease and the development of novel agents that target specific pathways involved in both the increased osteoclast formation and the suppressed osteoblast activity in myeloma provide new hope for these patients. The treatment of myeloma bone disease was revolutionized by clinical trials that demonstrated the significant benefit of intravenous bisphosphonate therapy in patients with myeloma bone disease. With the identification of many of the cytokines and chemoki
Data Loading...
